Clinical Trial Update: Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating intranasal inhalations of M2 macrophage soluble factors for developmental speech disorders in children; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Autism Spectrum Disorder
• Language Delay
• Language Developmental Disorder Expressive
• Language Developmental Disorder Receptive
• Speech Disorders in Children

Drugs mentioned

• M2 Macrophage Soluble Factors (intranasal inhalation)

Snippet

Sponsor: Russian Academy of Medical Sciences | Conditions: Language Delay, Language; Developmental Disorder, Expressive | Phase 1, Phase 2 | Status: COMPLETED